JIANGXI FUSHINE PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.5 CNY | -3.85% |
|
-2.87% | +22.86% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.65B 228M | Sales 2023 | 1.61B 223M | Capitalization | 5.04B 698M |
|---|---|---|---|---|---|
| Net income 2022 | -141M -19.52M | Net income 2023 | -201M -27.83M | EV / Sales 2022 | 4.55 x |
| Net Debt 2022 | 390M 54M | Net Debt 2023 | 895M 124M | EV / Sales 2023 | 3.69 x |
| P/E ratio 2022 |
-50.8
x | P/E ratio 2023 |
-25.3
x | Employees | 2,179 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.34% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.85% | ||
| 1 week | -2.87% | ||
| Current month | +1.77% | ||
| 1 month | +47.44% | ||
| 3 months | +59.50% | ||
| 6 months | +6.48% | ||
| Current year | +22.86% |
1 week
11.22
13.24
1 month
7.7213.24
Current year
5.6213.24
1 year
5.6214.33
3 years
5.6229.40
5 years
5.6229.40
10 years
3.2929.40
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 12-07-31 |
Guang Yang
DFI | Director of Finance/CFO | 37 | 08-12-31 |
Rong Wu Cheng
BRD | Director/Board Member | 55 | 04-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yan Li
BRD | Director/Board Member | 67 | 15-06-30 |
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 12-07-31 |
Wei Dong
BRD | Director/Board Member | 46 | 12-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 11.5 | -3.85% | 25,393,700 |
| 24-05-15 | 11.96 | -2.21% | 22,284,950 |
| 24-05-14 | 12.23 | -3.01% | 36,060,810 |
| 24-05-13 | 12.61 | +10.32% | 47,647,460 |
| 24-05-10 | 11.43 | -3.46% | 30,368,250 |
End-of-day quote Shenzhen S.E., May 15, 2024
More quotes
Jiangxi Fushine Pharmaceutical Co., Ltd. is principally engaged in research and development, manufacturing and sales of bulk drugs, pharmaceutical intermediates and related products. The Company's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The Company distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.
Sector
Pharmaceuticals
Calendar
2024-05-20
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +22.86% | 858M | |
| +32.36% | 694B | |
| +30.77% | 593B | |
| -1.60% | 371B | |
| +20.07% | 331B | |
| +6.04% | 290B | |
| +14.77% | 239B | |
| +9.13% | 209B | |
| -3.97% | 209B | |
| +9.27% | 169B |
- Stock Market
- Equities
- 300497 Stock
